Description overdue on 09.02.2012

Glucocorticosteroid . Main, the active ingredient - beclomethasone . Bekonaze ​​has anti-allergic, anti-inflammatory effects. Active ingredient of the drug inhibits the process of release of mediators of inflammation, increases the production of the phospholipase A2 inhibitor annexin (lipocortin), which reduces the production of arachidonic acid   and its metabolites (leukotrienes and prostaglandins). Beclomethasone inhibits the process of synthesizing prostaglandins , Cyclic endoperoxides and activating factor platelets . Bekonaze ​​inhibits the production of substances chemotaxis It reduces the rate of development of immediate allergic reactions and improves   mucociliary transport . Under the influence of beclomethasone decreased the number of mast cells   in the mucous membranes of the sinuses, nasal cavity, decreases swelling, mucus secretion, inhibits the production of macrophages, marginal decreases congestion   neutrophil . These mechanisms are actively involved in the formation of the allergic response. Beclomethasone increases the number of active beta-adrenergic receptors. Intranasal administration has no resorptive action . The local application at the recommended dosage does not lead to the formation of side effects that often occur with the use of glucocorticosteroids. Therapeutically significant effect formed gradually. Bekonaze ​​available as a metered nasal spray.

Indications and contraindications:

Bekonaze ​​prescribed for inflammatory processes in the nasal cavity of non-infectious origin, with recurrent course nasal polyposis , In allergic rhinitis (year-round seasonal flow variations). Bekonaze ​​is contraindicated in case of intolerance to beclomethasone. In glaucoma, amebiasis, hypothyroidism , Renal pathology system, myocardial infarction, herpes eye, systemic infections (bacterial, fungal origin), ulceration of the nasal septum, with pulmonary tuberculosis Recently endured injuries and operations on the nose, breastfeeding, pregnancy used with caution.

Side effects and overdose:

Application Bekonaze ​​can be accompanied by headaches, nosebleeds, rhinorrhea . In rare cases, there atrophy   and ulceration of the nasal mucosa, conjunctival hyperemia, perforation of the nasal septum, myalgia , Taste perversion, cough, increased sleepiness, increased intraocular pressure. In overdose recorded signs of oppression and the hypothalamic-pituitary-adrenal functions. There is no antidote.

Mode of application:

Bekonaze ​​applied intranasally: 2 inhalations in each nostril twice daily or 100 micrograms 3-4 hours. The day of not more than 1 mg.

Special instructions:

It is important to ensure that the drug had no contact with the eyes. Breastfeeding and child bearing Bekonaze ​​prescribed in exceptional cases, when evaluating the potential benefits and risks to the fetus or child. Reliable data on the safety of beclomethasone in lactating and pregnant women do not have.